Compare Neurocrine Biosciences Inc (NBIX) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Realty Income Corp — how do they compare? Neurocrine Biosciences Inc trades at $155.85 (market cap $15.77B), while Realty Income Corp trades at $60.29 (market cap $56.88B). The key difference: Realty Income Corp is far larger — about 3.6× Neurocrine Biosciences Inc's market cap, and Realty Income Corp pays a 5.42% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | O | |
|---|---|---|
Market Cap | $15.77B | $56.88B |
Sector | Health | Real Estate |
52-Week High | $185.50 | $67.56 |
52-Week Low | $123.10 | $55.93 |
Enterprise Value | $15.78B | $87.50B |
Dividend Yield | — | 5.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a 20.91% net income margin and robust revenue growth, with Q1 2026 EPS beating expectations. Recent news highlights institutional buying and pipeline progress, but safety concerns for Vykat XR have caused volatility.
The outlook is positive given analyst consensus of $207.07 price target and 86% buy ratings, supported by Ingrezza's growth and new drug launches. Key risks include drug safety issues, competitive pressures, and execution challenges in expanding the portfolio, which could impact shareholder returns amid current bearish technical trends.
Realty Income (O) trades at $61.02, down 0.38% with a bearish technical signal. The REIT maintains strong fundamentals with 92.6% gross margins and consistent dividend growth, recently increasing its monthly payout to $0.2715. However, the stock has missed earnings expectations for three consecutive quarters, and technical indicators show selling pressure with support at $60-61 levels. The company's $68.8 billion asset base supports its 5.3% dividend yield while debt levels have been trending upward.
O offers income investors a reliable dividend aristocrat with 25+ years of growth, but faces headwinds from interest rate sensitivity and recent earnings misses. The consensus price target of $66.50 suggests 9% upside potential, though technical weakness and rising debt-to-asset ratios warrant caution. The stock's appeal hinges on its ability to maintain AFFO growth amid a challenging rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
